Notify me when SILVERARC CAPITAL MANAGEMENT, LLC files a new 13F portfolio report.
⭐ Subscribe ⭐| Quarter | Holdings | Value $ | Bought | Sold | Net | Top Holdings | Form Type | Filing Time |
|---|---|---|---|---|---|---|---|---|
| Q4 2025 | 64 | $691,146,408 | +$192,526,982 | -$326,473,254 | -$133,946,272 | ABVX, COGT, URGN, KALV, CELC | 13F-HR | 12 Feb 2026, 15:37 |
| Q3 2025 | 73 | $690,726,077 | +$316,775,533 | -$212,675,890 | +$104,099,643 | ABVX, RYTM, RNA, NUVL, URGN | 13F-HR | 12 Nov 2025, 15:45 |
| Q2 2025 | 57 | $488,616,503 | +$105,743,622 | -$162,551,117 | -$56,807,495 | MRUS, AKRO, VRNA, URGN, RYTM | 13F-HR | 14 Aug 2025, 14:19 |
| Q1 2025 | 67 | $478,648,027 | +$158,197,332 | -$97,189,838 | +$61,007,494 | VRNA, MRUS, NUVL, AKRO, INSM | 13F-HR | 14 May 2025, 15:28 |
| Q4 2024 | 58 | $447,221,219 | +$114,180,498 | -$103,901,770 | +$10,278,728 | NUVL, MRUS, INSM, VRNA, AKRO | 13F-HR | 14 Feb 2025, 10:00 |
| Q3 2024 | 68 | $443,751,022 | +$83,622,091 | -$77,828,925 | +$5,793,166 | NUVL, MRUS, INSM, RNA, ERAS | 13F-HR | 14 Nov 2024, 08:44 |
| Q2 2024 | 66 | $405,072,155 | +$158,288,541 | -$74,212,470 | +$84,076,071 | MRUS, NUVL, RNA, URGN, ERAS | 13F-HR | 14 Aug 2024, 13:44 |
| Q1 2024 | 73 | $356,621,057 | +$116,375,700 | -$143,364,975 | -$26,989,275 | MRUS, SLDB, MORF, ORIC, MRSN | 13F-HR | 14 May 2024, 17:37 |
| Q4 2023 | 64 | $324,239,019 | +$138,179,736 | -$128,653,186 | +$9,526,550 | MRUS, MRSN, MORF, NUVL, PSTX | 13F-HR | 14 Feb 2024, 10:28 |
| Q3 2023 | 68 | $268,426,880 | +$92,175,500 | -$88,107,477 | +$4,068,023 | IMGN, MORF, MRUS, SLNO, ITCI | 13F-HR | 13 Nov 2023, 09:29 |
| Q2 2023 | 77 | $296,174,542 | +$111,435,164 | -$56,068,534 | +$55,366,630 | IMGN, MRUS, MORF, SDGR, KRYS | 13F-HR | 14 Aug 2023, 09:53 |
| Q1 2023 | 67 | $222,531,048 | +$82,994,774 | -$124,825,737 | -$41,830,963 | MRUS, MGNX, VRAYQ, PSTX, ORIC | 13F-HR | 15 May 2023, 09:57 |
| Q4 2022 | 81 | $290,450,714 | +$97,459,926 | -$66,162,971 | +$31,296,955 | MDGL, BLU, PSTX, VRAYQ, XENE | 13F-HR | 14 Feb 2023, 12:29 |
| Q3 2022 | 69 | $235,783,000 | +$76,023,126 | -$65,129,628 | +$10,893,498 | BLU, VCYT, AKRO, MORF, COGT | 13F-HR | 28 Oct 2022, 17:06 |
| Q2 2022 | 59 | $213,354,000 | +$71,945,964 | -$47,556,849 | +$24,389,115 | ITCI, BLU, VCYT, CERS, MRUS | 13F-HR | 25 Jul 2022, 15:27 |
| Q1 2022 | 65 | $174,518,000 | +$46,121,715 | -$41,751,709 | +$4,370,006 | ITCI, SRRA, VCYT, CTIC, MRUS | 13F-HR | 13 May 2022, 16:32 |
| Q4 2021 | 68 | $223,164,000 | +$83,744,639 | -$34,271,271 | +$49,473,368 | IMGN, BHVN, ITCI, MRUS, VCYT | 13F-HR | 14 Feb 2022, 09:12 |
| Q3 2021 | 79 | $172,545,000 | +$46,483,907 | -$60,008,394 | -$13,524,487 | BHVN, VCYT, MRTX, MRUS, AMYT | 13F-HR | 15 Nov 2021, 15:01 |
| Q2 2021 | 91 | $187,003,000 | +$75,403,116 | -$60,679,276 | +$14,723,840 | DRNA, MRUS, MRTX, VCYT, MORF | 13F-HR | 16 Aug 2021, 15:24 |
| Q1 2021 | 88 | $178,477,000 | +$63,840,119 | -$54,994,092 | +$8,846,027 | ACRS, CRIS, VCEL, INSM, AMYT | 13F-HR | 17 May 2021, 18:02 |
| Q4 2020 | 81 | $163,750,000 | $0 | $0 | $0 | VCEL, ITCI, DCTH, INSM, AMYT | 13F-HR | 16 Feb 2021, 17:09 |